Literature DB >> 2481487

Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives.

C Gavériaux1, D Boesch, J J Boelsterli, P Bollinger, M K Eberle, P Hiestand, T Payne, R Traber, R Wenger, F Loor.   

Abstract

Cyclosporin A (Sandimmune) increased the in vitro susceptibility of 'parental' and 'multidrug-resistant' (MDR) chinese hamster ovary (CHO) cell lines to three anti-tumour drugs: colchicine, daunomycin, and vincristine. Several immunosuppressive or non-immunosuppressive derivatives of cyclosporin (Cs) were compared for their ability to sensitise both parental and MDR cells to chemotherapeutic agents. Although 5-10-fold increases of sensitivity to anti-tumour drugs could be obtained for cells of the parental line with several Cs-derivatives, the largest 'gains' of sensitivity (chemosensitisation) were obtained for the cells of the MDR line and with only some of the Cs derivatives. The MDR cells employed displayed the typical MDR phenotype. However, we found no correlation between the immunosuppressive activity of Cs derivatives and their capacity to reverse MDR and all four possible combinations of these two activities could indeed be shown among the tested Cs derivatives. This study demonstrates for the first time that some immunosuppressive Cs can be devoid of chemosensitising activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481487      PMCID: PMC2247253          DOI: 10.1038/bjc.1989.381

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line.

Authors:  A M Van der Bliek; T Van der Velde-Koerts; V Ling; P Borst
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

Review 2.  Resistance to multiple chemotherapeutic agents in human cancer cells.

Authors:  M M Gottesman; I Pastan
Journal:  Trends Pharmacol Sci       Date:  1988-02       Impact factor: 14.819

3.  Reduced permeability in CHO cells as a mechanism of resistance to colchicine.

Authors:  V Ling; L H Thompson
Journal:  J Cell Physiol       Date:  1974-02       Impact factor: 6.384

4.  The effects of cyclosporins on the cell cycle of t-lymphoid cell lines.

Authors:  M Koponen; A Grieder; F Loor
Journal:  Exp Cell Res       Date:  1982-08       Impact factor: 3.905

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

7.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

8.  Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.

Authors:  W T Beck; M C Cirtain; A T Look; R A Ashmun
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

9.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.

Authors:  L M Slater; P Sweet; M Stupecky; M W Wetzel; S Gupta
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

View more
  12 in total

Review 1.  Determinants of passive drug entry into the central nervous system.

Authors:  M D Habgood; D J Begley; N J Abbott
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

2.  Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype.

Authors:  P A te Boekhorst; J van Kapel; M Schoester; P Sonneveld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Chemosensitisation of a drug-sensitive parental cell line by low-dose cyclosporin A.

Authors:  P R Twentyman; K A Wright
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Rgg protein structure-function and inhibition by cyclic peptide compounds.

Authors:  Vijay Parashar; Chaitanya Aggarwal; Michael J Federle; Matthew B Neiditch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

5.  Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Authors:  Alison C Macleod; Lillian R Klug; Janice Patterson; Diana J Griffith; Carol Beadling; Ajia Town; Michael C Heinrich
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

6.  Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type beta.

Authors:  H J Schluesener; R Meyermann
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.

Authors:  W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 8.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 9.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Reversal of multidrug resistance by novel cyclosporin A analogues and the cyclopeptolide SDZ 214-103 biosynthesized in vitro.

Authors:  K Schwabe; G Steinheider; A Lawen; R Traber; A Hildebrandt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.